Inqanaba lesi-3 Nonyango oluNgelulo oluNcinane lweSeli yeMiphunga yoMhlaza: IiNqanaba ngo-2026 kunye namazinga okusinda 

Inqanaba lesi-3 lonyango olungelulo oluncinci lomhlaza wemiphunga ngo-2026 iye yaguquka yaba yindlela eguquguqukayo, ye-multimodal edibanisa i-immunotherapy, unyango olujoliswe kuyo, kunye noqhaqho oluchanekileyo. Impumelelo yangoku igxile kwi-neoadjuvant immune-checkpoint inhibitors ukuthoba amathumba phambi kotyando kunye nenoveli ye-antibody-drug conjugates (ADCs) yotshintsho oluthile lwemfuza. Amazinga okusinda ayaphucuka kakhulu, kunye nophononongo lwakutsha nje olubonisa ukusinda okungahambelaniyo ngaphandle kweenyanga ezili-15 kwizigulana ezifumana unyango oludityanisiweyo lwe-immunotherapy emva kwe-chemoradiation.

Ukuqonda iNqanaba lesi-3 loMhlaza woMphunga weSeli engeNcinci ngo-2026

Inqanaba lesi-3 lomhlaza wemiphunga yeseli engeyincinci (NSCLC) limele ixesha elibalulekileyo kwi-oncology apho isifo sisasazeke kwii-lymph nodes ezikufutshane kodwa hayi kumalungu akude. Eli nqanaba lihlala lichazwa njengelihamba phambili ekuhlaleni kwaye lineendlela ezininzi, lifuna amacebo onyango lomntu. Ngo-2026, inkcazo yokunyangeka iye yanda, kwaye uninzi lwezigulana ebezithathwa ngokuba "azichanekanga" ngoku ziye zaba ngabaviwa botyando olunenjongo yonyango ngenxa yonyango olusebenzayo.

Ubunzima beNqanaba lesi-3 le-NSCLC lilele ekuhlukeni kwayo. Ezinye izigulana zikhona ngokubandakanyeka okuncinci kwe-nodal ezifanelekileyo utyando olukhawulezileyo, ngelixa ezinye zinesifo esikhulu esifuna unyango lwe-systemic kuqala. Indlela yanamhlanje ibeka izigulana zibe ngamaqela anokuphinda ahlaziywe, anokuphinda ahlaziywe, kwaye angakwazi ukuchaswa ukuze alungelelanise ulandelelwano lwechemotherapy, radiation, immunotherapy, kunye nongenelelo lotyando.

• Inokuphinda isuswe: Amathumba anokususwa ngokupheleleyo ngotyando ekuxilongeni.
• Okunokuthi kucandeke kwakhona: Amathumba anokuthi asebenze emva konyango lwe-neoadjuvant (phambi kotyando).
• Ayichaswanga: Isifo esiqhubela phambili ekuhlaleni apho utyando lungenzeki; unyango nge-chemoradiation eqinisekileyo elandelwa lunyango lokudibanisa.

Ukulinganisa okuchanekileyo kusetyenziswa i-imaging ephezulu kunye neprofayili yemolekyuli ngoku yinto eqhelekileyo. Ukuchonga utshintsho lwabaqhubi olufana ne-EGFR, ALK, okanye i-HER2 kubalulekile, njengoko ichaza ukuba isigulane sizuza kwi-tyrosine kinase inhibitors (TKIs) okanye i-antibody-drug conjugates kunokuba i-immunotherapy eqhelekileyo yodwa.

Ukuphumelela kwiNeoadjuvant kunye nePerioperative Therapy

Olona tshintsho lubalulekileyo kwi isigaba 3 non small cell lung cancer unyango kule minyaka mibini idlulileyo kukwamkelwa ngokubanzi kwe-neoadjuvant chemo-immunotherapy. Esi sicwangciso siquka ukulawula ichemotherapy edityaniswe ne-immune checkpoint inhibitors phambi kotyando. Injongo kukuphumeza i-Pathological Complete Response (pCR), apho kungekho ziseli zomhlaza ezisebenzayo zifumaneka kwi-specimen yotyando, ehambelana kakhulu nokuphila kwexesha elide.

Idatha yeklinikhi eboniswe kwiinkomfa ezinkulu ze-oncology ekuqaleni kwe-2026 igxininisa ukusebenza kwe-PD-1 inhibitors kwesi silungiselelo. Iiarhente ezifana ne-sintilimab kunye ne-toripalimab zibonise iziphumo ezinamandla ekunciphiseni amathumba kunye nokucoca i-lymph nodes. Kwizigulane ezine-squamous cell carcinoma, ezi ndibaniselwano zibonise amazinga aphezulu okuphendula, okwenza ukuba i-R0 ikhuphe ii-rections (ukususwa ngokupheleleyo kunye nemida engalunganga).

Indima yokuJonga i-MRD

Uphuhliso oluphambili ngo-2026 ludibaniso lokubeka iliso kwiSifo esiNcinane esiSasalelayo (MRD). Ngokuhlalutya i-tumor ejikelezayo ye-DNA (ctDNA) egazini emva kotyando, i-oncologists inokubona isifo se-microscopic esiphosayo. Uphononongo lwakutsha nje lwamaziko amaninzi olubandakanya i-adjuvant aumolertinib yezigulane eziguqukayo ze-EGFR zisebenzise i-MRD ukukhokela ubude bonyango. Ukuba i-MRD ihlala ingalunganga, ezinye iiprothokholi zicebisa ukuba kuthotywe unyango lokunciphisa ubuthi, ngelixa i-MRD elungileyo ibangela ungenelelo oluqilima.

Le ndlela ichanekileyo iqinisekisa ukuba izigulane zifumana kanye umlinganiselo wonyango eziwufunayo. Ithintela unyango olugqithisileyo kwabo sele bephilisiwe ngotyando kwaye ibonelela ngonyango lokusindisa kwangethuba kwabo basemngciphekweni omkhulu wokuphindaphinda. Ukusetyenziswa kwe-MRD ngokukhawuleza kuba yi-biomarker eqhelekileyo kwizilingo zeklinikhi kwaye inefuthe ekwenzeni izigqibo zehlabathi lokwenyani kulawulo lweSigaba 3.

I-Chemoradiation ecacileyo kunye nokudibanisa i-Immunotherapy

Kwizigulane ezineNqanaba lesi-3 le-NSCLC elingenakulinganiswa, i-chemoradiation efanayo (cCRT) ihlala ingumqolo wokhathalelo. Nangona kunjalo, imeko ye-post-radiation iye yatshintshwa yi-consolidation immunotherapy. I-paradigm esekwe yidatha yolingo yangaphambili yePACIFIC iye yaqiniswa kwaye yandiswa ngamagosa amatsha kunye nedatha yokulandela ixesha elide ekhoyo ngo-2026.

Uhlaziyo kwiZicwangciso zoNxibelelwano

Iziphumo zakutsha nje ezivela kuphononongo lwe-CONSIST, olunikezelwe ekuqaleni kuka-2026, lubonelela ngobungqina obubambekayo bokusetyenziswa kwe-sintilimab njengonyango lokudibanisa olulandela i-cCRT. Kolu phando lunokwenzeka, lwamaziko amaninzi, izigulana eziphumelele ulawulo lwesifo emva kwe-chemoradiation zafumana i-sintilimab ukuya kuthi ga kwiinyanga ezingama-24. Iziphumo zibonise ukusinda kwe-median progression-free (PFS) yeenyanga ze-15.6, kunye namazinga okusinda eenyanga ezingama-24 afikelela phantse kwi-80%.

Oku kuqinisekisa ukuba i-PD-1 inhibitors yindlela esebenzayo kunye nenamandla kwi-PD-L1 inhibitors kwisimo sokudibanisa. Iprofayili yokhuseleko yayilawuleka, kunye namazinga aphantsi eziganeko ezimbi ezinxulumene ne-immune-immune. Ezi nkcukacha zinika ithemba kwizigulane ezinokuthi zinganyamezeli ezinye ii-immunotherapies okanye zihlala kwimimandla apho amachiza athile afikeleleka ngakumbi.

• Umgangatho Wokhathalelo: I-chemotherapy esekelwe kwiplatinam kunye nemitha.
• Udibaniso: Ukuqaliswa kwe-immunotherapy kwiiveki ezi-1-6 emva kokugqitywa kwe-cCRT.
• Ubude bexesha: Ngokuqhelekileyo kuqhubeka iinyanga ezili-12 ukuya kwezingama-24 ukuba akukho nkqubela phambili eyenzekayo.

Ukukhethwa kwe-arhente kaninzi kuxhomekeke kwimvume yengingqi kunye nemiba ethile yesigulane. Ngelixa i-durvalumab ibeka umgangatho wokuqala, ukungena kwe-PD-1 inhibitors yasekhaya nakwamanye amazwe kuye kwakha umhlaba okhuphisanayo onceda izigulane ngokunyuka kokufikelela kunye neendlela ezahlukeneyo zokwenza.

UNyango ekuJoliswe kulo kuMqhubi-oGuquliweyo kwiNqanaba lesi-3 le-NSCLC

I-subset ye-Stage 3 yezigulane ze-NSCLC igcina abaqhubi abathile bezofuzo, ngokukodwa iinguqu ze-EGFR. Ngokwembali, ezi zigulana zaphathwa ngokufanayo nezo zingaguqukiyo, kodwa u-2026 uphawula unyaka wokwahlukana okwahlukileyo kwiindlela zonyango. Ukusebenza kwe-EGFR-Tyrosine Kinase Inhibitors (TKIs) kwi-adjuvant kunye ne-neoadjuvant setting ngoku ibhalwe kakuhle.

I-Adjuvant EGFR-TKI Therapy

Idatha ekhutshwe ekuqaleni kwe-2026 malunga ne-aumolertinib kunye ne-osimertinib igxininisa ixabiso labo ekunqandeni ukuphindaphinda kwezigulane ze-EGFR-mutant. Uphononongo lwehlabathi lokwenyani oluvela eTshayina naseYurophu lubonise ukuba unyango lwe-TKI ye-adjuvant kwandisa kakhulu ukusinda okungenasifo xa kuthelekiswa nechemotherapy kuphela. Kwinqanaba le-IA ukuya kwizigulane ze-IIA eziye zafumana uqhaqho olupheleleyo, ii-TKI zomlomo zithandwa kakhulu ngenxa yeeprofayili zazo ezithandekayo kunye namazinga aphezulu okuthotyelwa.

Ngaphaya koko, uphando luphonononga indima yee-TKIs kwimeko ye-neoadjuvant. Ulingo lwesigaba sakwangoko lucebisa ukuba unyango lwe-TKI lwexesha elifutshane phambi kotyando lunokuthoba ngokufanelekileyo amathumba kwizigulana ezine-EGFR, nangona uqwalaselo ngononophelo lweendlela zokuxhathisa kufuneka. Uhlalutyo lwe-meta yenethiwekhi enikezelwe kwiinkomfa zamva nje zixhasa ukuphakama kwe-TKI yesizukulwana sesithathu kwizizukulwana zangaphambili kumxholo we-adjuvant.

Ujoliso olusakhulayo: I-HER2 kunye ne-KRAS

Ngaphandle kwe-EGFR, ezinye iithagethi zifumana ukutsalwa. Iinguqu ze-HER2, nangona zingaxhaphakanga kangako, ngoku ziyasebenza ngokuvunywa kwe-trastuzumab deruxtecan (T-DXd). Le conjugate ye-antibody-drug conjugate ibonise ukusebenza okumangalisayo kwiisetingi ze-metastatic kwaye iphandwa isifo senqanaba langaphambili. Ngokufanayo, ii-inhibitors ze-KRAS G12C ezifana ne-elisrasib zibonisa isithembiso kwiSigaba 1/2 solingo lwe-NSCLC enyangwa ngaphambili, evula iingcango zokudityaniswa kwexesha elizayo kwiiprothokholi zeNqanaba lesi-3.

Ukuqhubela phambili koTyando kunye nokudityaniswa kwe-Multimodal

Utyando luhlala lukhona kuphela unyango olunokubakho kumhlaza wemiphunga wasekhaya, kwaye indima yalo kwiSigaba 3 sesi sifo sichazwa ngokutsha ngonyango olungcono lwenkqubo. Ingcamango "yokuguqulwa kokuhlinzwa" ingundoqo kwi-algorithms yonyango ye-2026. Izigulane eziye zaqala ngezifo ezingenakunqandwa ngenxa yokubandakanyeka kwe-nodal okanye ubukhulu be-tumor bangenza utyando emva kokuphendula ngamandla kunyango lwe-neoadjuvant.

Iikhrayitheriya zoTshintsho loTyando

Ukugqiba ngexesha lokusebenza emva konyango lwe-neoadjuvant kufuna iqela lezinto ezininzi. Imiba ephambili ibandakanya ubungakanani be-tumor shrinkage, ukucocwa kwee-lymph nodes ze-mediastinal, kunye nokugcinwa kwempilo yesigulana. Ubuchwephesha bokucinga obuphezulu, kubandakanya i-PET-CT kunye ne-MRI, nceda oogqirha botyando bavavanye ukuphindaphindeka kwakhona ngokuchanekileyo kunanini ngaphambili.

Ubuchwephesha obungenabuqhetseba obuncinci, obufana neVideo-Assisted Thoracoscopic Surgery (VATS) kunye notyando oluncediswa yirobhothi, lusetyenziswa ngakumbi nakwiimeko ezinzima zeSigaba se-3. Ezi ndlela zinciphisa ixesha lokubuyisela kwaye zivumela izigulane ukuba ziqalise unyango lwe-adjuvant ngokukhawuleza. Ukudityaniswa kweenkqubo ze-intraoperative navigation systems ziqhubekisela phambili ukuchaneka kwe-lymph node dissection, ukuqinisekisa ukubekwa okuchanekileyo kunye nokulawulwa kwendawo.

• UVavanyo lwangaphambili: Ukuhlelwa kwakhona emva konyango lwe-neoadjuvant ukuqinisekisa ukuhla.
• Indlela yoTyando: Ukukhethwa kwiindlela zokuhlasela kancinci xa kunokwenzeka.
• Ukhathalelo lwasemva kotyando: Iiprothokholi zokubuyisela ngokukhawuleza ukuququzelela unyango lwe-adjuvant ngexesha elifanelekileyo.

I-synergy phakathi kwe-oncology yonyango kunye nokuhlinzwa kwe-thoracic ayizange ibe namandla. Iingxoxo zebhodi yethumba rhoqo ziqinisekisa ukuba isigulana ngasinye seNqanaba lesi-3 sifumana isicwangciso esilungelelanisiweyo esonyusa ithuba lokunyangwa ngelixa kuncitshiswa ukugula.

Ukuthelekiswa kweeNdlela zoNyango kwiNqanaba lesi-3 le-NSCLC

Ukukhetha indlela yonyango efanelekileyo kuxhomekeke kwizinto ezininzi ezibandakanya ukuhlanjululwa, isimo se-molecular, kunye nesimo sokusebenza. Le theyibhile ilandelayo ithelekisa iindlela eziphambili ezisebenzayo ngoku ngo-2026.

Olu thelekiso lubonisa ukuba akukho sisombululo silinganayo. Umkhwa uhamba ngokucacileyo ukuya kumayeza omntu apho iimpawu zebhayoloji zethumba ziqhuba ukhetho lonyango. Ngokomzekelo, isigulana esinokuguqulwa kwe-EGFR sinokuthi sidlule kunyango lwe-immunotherapy ngokuthanda ii-TKIs, ngelixa isigulana esine-PD-L1 ephezulu yokubonakalisa kwaye akukho tshintsho luya kuba ngumviwa oyintloko we-chemo-immunotherapy.

Amazinga okusinda kunye nezinto ezibikezelwa ngo-2026

Ukusinda izibalo ze isigaba 3 non small cell lung cancer unyango ziyaphucuka, zibonisa impembelelo yolu nyango lutsha. Ngelixa izinga lokusinda leminyaka emi-5 lijikeleza malunga ne-15-30%, idatha yangoku ibonisa ukuba la manani ayenyuka, ngakumbi kumaqela angaphantsi asabela kakuhle kunyango logonyo.

Impembelelo ye-Immunotherapy ekuSindeni kwexesha elide

Ukuqaliswa kokuhlanganiswa kwe-immunotherapy kuye kwadala "umsila" kwi-curve yokusinda, oku kuthetha ukuba i-subset yezigulane zifezekisa ulawulo lwezifo zexesha elide ezazinqabile ngaphambili. Uphononongo lubonisa ukuba izigulana ezigqiba ikhosi epheleleyo yonyango lokuqinisa kwaye zihlala zingenankqubela-phambili kwiminyaka emibini zinethuba eliphezulu lokusinda ixesha elide.

Ngokukwanjalo, ukufezekiswa kwe-pCR kulandela unyango lwe-neoadjuvant sisibonisi esinamandla sesiphumo. Izigulana ezifikelela kwi-pCR zihlala zifumana amazinga okusinda ngaphandle kwesiganeko adlula i-80% kwiminyaka emithathu. Oku kwenze i-pCR yasisiphelo esibambeneyo kulingo oluninzi lwezonyango, kukhawulezisa uphuhliso lwendibaniselwano yamachiza amatsha.

Iiguquguquko zePrognostic

Izinto ezininzi zinefuthe kwi-prognosis yomntu:

• Ubume beNodal: Inani kunye nendawo yee-lymph nodes ezibandakanyekayo (i-N1 vs. N2 vs. N3) zihlala ziyimimiselo ebalulekileyo.
• Inkangeleko yemolekyuli: Ubukho botshintsho olusebenzayo ngokuqhelekileyo lubonelela ngeziphumo ezingcono ngonyango olujoliswe kuyo.
• Isimo sokuSebenza: Izigulana ezinesimo esihle sokusebenza zinyamezela unyango olunobundlongondlongo lwe-multimodal ngcono.
• Impendulo esuka ku Induction: Iqondo le-tumor shrinkage emva konyango lokuqala liqikelela impumelelo yotyando kunye nokusinda.

Kubalulekile ukuqaphela ukuba amazinga okusinda yi-avareji. Iziphumo zomntu ngamnye ziyahluka ngokubanzi ngokusekelwe kwindibaniselwano ethile yonyango olufunyenweyo kunye nokuziphatha kwebhayoloji yomhlaza. Injongo ye-oncology yanamhlanje kukutshintsha isigulana ngasinye singene kudidi olufanelekileyo lwe-prognostic ngongenelelo oluchanekileyo.

Ukulawula iZiphumo eziPhakamileyo kunye noMgangatho woBomi

Unyango oluqatha lweNqanaba lesi-3 le-NSCLC liza nemingcipheko yetyhefu ebalulekileyo. Ukulawula ezi ziphumo bezingalindelekanga kubalulekile ukugcina ubunzulu bedosi kunye nomgangatho wobomi. Iiprofayili zempembelelo yecala zahluke kakhulu phakathi kwechemotherapy, radiation, immunotherapy, kunye neearhente ezichongiweyo.

Iziganeko ezimbi eziNxulumene noKhuseleko lwamajoni omzimba (irAEs)

I-Immunotherapy inokubangela ukuvuvukala kwizitho eziphilileyo, ezibizwa ngokuba yi-irAEs. Imiba eqhelekileyo ibandakanya i-pneumonitis, i-colitis, i-dermatitis, kunye nokuphazamiseka kwe-endocrine njenge-hypothyroidism. Kuphononongo lwe-CONSIST, i-pneumonitis yayiyinkxalabo ephawulekayo, eyenzeka malunga ne-23% yezigulane, nangona iimeko ezinzima zazinqabile. Ukufunyaniswa kwangaphambili kunye nokulawulwa nge-corticosteroids kubalulekile.

Izigulana ezifumana ukuqinisa amajoni omzimba emva kokusasazeka kwemitha zisemngciphekweni kancinane wokutyhefeka kwemiphunga. Ukujongwa ngokusondeleyo kunye ne-CT scans rhoqo kunye nokuhlolwa kweempawu yiprotocol eqhelekileyo. Uninzi lwe-IRAEs lubuyiselwa umva ukuba lubanjwe kwangethuba, luvumela izigulane ukuba ziqhubeke okanye ziqalise unyango ngokukhuselekileyo.

Ubuthi obuvela kwiiNyango eziJoliswe

I-EGFR-TKIs ngokubanzi ineprofayili yetyhefu eyahlukileyo, ephawulwa kukuqhambuka kwesikhumba, urhudo, kunye nesifo semiphunga se-interstitial. Ngelixa ihlala inyamezeleka ngakumbi kune-chemotherapy, ulawulo olungapheliyo lufuna uqwalaselo. Isizukulwana esitsha se-TKIs siphucule imida yokhuseleko, kodwa ukujongwa kwentliziyo kunye neemviwo ze-ophthalmologic zingacetyiswa ngokuxhomekeke kwi-arhente ethile.

• Unyango ngamachiza: Isicaphucaphu, ukudinwa, neutropenia.
• Imitha: I-Esophagitis, ukusabela kwesikhumba, ukukhathala.
• I-Immunotherapy: Iimpendulo ze-Autoimmune ezichaphazela imiphunga, amathumbu, ulusu, okanye iihomoni.
• Unyango olujolisiweyo: Irhashalala, urhudo, ityhefu ethile yamalungu.

Amaqela anika inkxaso adlala indima ebalulekileyo ekulawuleni ezi mpawu. Inkxaso yesondlo, unyango lomzimba, kunye nokululekwa kwengqondo yinxalenye ebalulekileyo yohambo lonyango, ukunceda izigulane zigcine amandla kunye nokuziphatha kuyo yonke irejimeni enzima.

Ubume bexesha elizayo: Iindlela ezisakhulayo kunye novavanyo lwezonyango

Intsimi ye isigaba 3 non small cell lung cancer unyango iyavela ngokukhawuleza, kunye nolingo lwezonyango oluninzi olulungele ukucacisa imigangatho kwiminyaka ezayo. Ugxininiso lutshintshela kwi-doublet immunotherapy, inoveli ye-ADCs, kunye nokukhethwa kwezigulane ezisulungekileyo kusetyenziswa i-biopsies yolwelo.

Isizukulwana esilandelayo se-Antibody-Drug Conjugates

Ii-ADCs ziyanda ngaphaya kwe-HER2. Ulwakhiwo olutsha olujolise kwi-TROP2, B7-H3, kunye nezinye ii-antigens kuphuhliso. La machiza anika amandla okuzisa ichemotherapy enamandla ngokuthe ngqo kwiiseli zomhlaza ngelixa ugcina izicubu eziqhelekileyo. Idatha yakwangoko kwiisetingi zemetastatic iyathembisa, kwaye iimvavanyo ngoku zivulelwa isifo senqanaba langaphambili, kubandakanya iNqanaba lesi-3.

Umzekelo, ii-arhente ezifana ne-YL202/BNT326 (a HER3 ADC) ziphandwa kulingo lweSigaba sesi-2 se-NSCLC. Ukuba ngaba yimpumelelo, ezi zinokubonelela ngeendlela zokukhetha izigulane ezingaphenduliyo kwi-immunotherapies yangoku okanye i-agent ekujoliswe kuyo. Ukuguquguquka kwee-ADC kubenza ilitye lembombo lezicwangciso zexesha elizayo ezidityanisiweyo.

Izitofu zokugonya ezenzelwe wena kunye noNyango lweSellula

Izitofu zokugonya zomhlaza ze-RNA (mRNA) ezenzelwe ukuguqulwa kwethumba elithile lesigulana zingena kulingo lwasemva kwexesha. Xa zidityaniswe ne-checkpoint inhibitors, ezi zitofu zijolise ekuvuseleleni impendulo eyomeleleyo kunye nethe ngqo ye-immune. Ukongeza, unyango lweeseli olwamkelekileyo olufana ne-TILs (i-Tumor-Infiltrating Lymphocytes) luyaphononongwa ukuze lufumane amathumba aqinileyo, abonelela ngendlela enokubakho kumatyala aphikisayo.

Ukudityaniswa kobukrelekrele bokwenziwa kwisicwangciso sonyango nako kukhawuleza. Ii-algorithms ze-AI zinokuhlalutya iiseti zedatha enkulu yokucinga, i-genomics, kunye neziphumo zeklinikhi ukuxela kwangaphambili ulandelelwano lonyango olungcono kwisigulane ngasinye. Eli nqanaba lobuntu lithembisa ukwandisa ukusebenza kakuhle ngelixa unciphisa ubutyhefu obungeyomfuneko.

Imibuzo Ebuzwa Rhoqo malunga neNqanaba lesi-3 loNyango lwe-NSCLC

Izigulane kunye neentsapho zihlala zinemibuzo emininzi xa zijongene nokuxilongwa kweNqanaba lesi-3. Nazi iimpendulo kwimibuzo eqhelekileyo esekwe kwimvumelwano yezonyango ka-2026.

Ingaba inqanaba lesi-3 lomhlaza wemiphunga liyanyangeka?

Ewe, iNqanaba lesi-3 le-NSCLC linokunyangeka, ngakumbi ngonyango lwangoku lwe-multimodal. Inkcazo “yonyango” ihlala ithetha ukuhlala ungenasifo iminyaka emihlanu nangaphezulu. Ngokufika kwe-neoadjuvant immunotherapy kunye neendlela eziphuculweyo zotyando, inani lezigulana ezifumana ukuxolelwa kwexesha elide liyanda.

Luhlala Ixesha Elingakanani Unyango?

Ubude bexesha lonyango luyahluka. Unyango lwe-Neoadjuvant luhlala luhlala imijikelo emi-3-4 (malunga neenyanga ezi-2-3), lulandelwa lutyando kunye nokubuyiselwa. I-Adjuvant okanye unyango lokudibanisa lunokuqhubeka ukuya kwi-1-2 iminyaka. Unyango olujoliswe kuyo lunokuthi luthathwe ngomlomo iminyaka emininzi ngokuxhomekeke kunyamezelo kunye nesimo sesifo.

Kwenzeka Ntoni Ukuba Umhlaza Ubuyile?

Ukuba ukuphindaphinda kwenzeka, ukhetho lonyango luxhomekeke kwisiza kunye nobungakanani bembuyekezo. Ukuvela kwakhona kwendawo kunokunyangwa ngotyando okanye ngemitha ukuba ayisetyenziswanga ngaphambili. I-metastases ekude ilawulwa ngokuqhelekileyo ngonyango lwenkqubo, kubandakanywa i-immunotherapies yomgca wesibini, ii-agent ezijoliswe kuzo, okanye izilingo zonyango. Ukufumaneka kweendidi ezahlukeneyo zamachiza kuthetha ukuba kukho phantse kusoloko kukho imigca yonyango elandelayo enokuphononongwa.

• Ukubek' esweni: Ukutyelela rhoqo kunye nokuskena kubalulekile ukuze kubonwe kwangethuba ukuphindaphinda.
• Iinketho zomgca wesibini: Bandakanya iindidi ezahlukeneyo zamachiza angasetyenziswanga kwisimo sokuqala.
• Uvavanyo lweklinikhi: Ukubonelela ngofikelelo kunyango olukumgangatho ophezulu ongekafumaneki ngokubanzi.

Isiphelo: Ixesha elitsha leThemba kunye nokuchaneka

Imbonakalo yomhlaba ye isigaba 3 non small cell lung cancer unyango ngo-2026 uchazwa ngokuba nethemba kunye nokuchaneka. Utshintsho olusuka kwindlela yobukhulu obunye ukuya kwisicwangciso somntu ophezulu luvelise ukuphucuka okubonakalayo ekusindeni kunye nomgangatho wobomi. Ukususela ekusetyenzisweni ngokubanzi kwe-neoadjuvant immunotherapy ukuya ekucokiseni ukhathalelo lwe-adjuvant ekujoliswe kulo, izigulana zinezixhobo ezininzi kunangaphambili zokulwa nesi sifo.

Izinto eziphambili ezithatha izigulane kunye nababoneleli zibandakanya ukubaluleka kovavanyo olubanzi lweemolekyuli, ixabiso leebhodi ze-tumor multidisciplinary, kunye nemfuneko yokubambelela kunyango lokudibanisa. Njengoko uphando luqhubeka nokuvula iithagethi zebhayoloji ezintsha kunye nokucokisa iiprothokholi ezikhoyo, umkhondo weNqanaba lesi-3 le-NSCLC unyuka ngokuthe ngcembe. Intsebenziswano phakathi koluntu lophando lwehlabathi, ubungqina bokwabelana ngedatha kwiinkomfa ezifana ne-ELCC kunye ne-ASCO, iqinisekisa ukuba le nkqubela ifikelela kwizigulane ngokukhawuleza.

Ngelixa imingeni isekhona, ngakumbi ekulawuleni ubutyhefu kunye nokufikelela kukhathalelo kwihlabathi jikelele, inkqubela phambili eyenziwe kule minyaka imbalwa idlulileyo ayinakuphikiswa. Nabani na ojonga ukuxilongwa kweNqanaba lesi-3 namhlanje, umyalezo ucacile: kukho iindlela ezisebenzayo, ezixhaswa yinzululwazi ezikhokelela kubomi bexesha elide, kwaye ikamva libambe isithembiso esikhulu ngakumbi.